drugset
drugset / Trial / NCT02871570

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570 ↗

Phase 1 Completed 16 enrolled GlycoMimetics Incorporated
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.

Timeline

Start
2016-09
Primary completion
2017-02
Completion
2017-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivipansel Small molecule 840 mg Intravenous

Indications

No indication recorded.